Skip to content
DataLookout
Menu

YNSZLYY-RADGELNCT07886320

Adapalene Gel for Acute Radiation-Induced Skin Injury

StatusRecruiting
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 1 with changes below, 1 re-verified with no change.

  1. Study First Submitted

Endpoints

Primary

RTOG/EORTC Acute Radiation Morbidity Score for Skin Reactions in the Irradiated Field (Score Range: 0 to 4; Lower Scores Indicate Better Outcome)
Timeframe: From randomization through completion of radiotherapy and follow-up, up to 6 weeks.

Arms and interventions

AdapaleneExperimental

Intervention Name: Adapalene gel 0.1% Intervention Type: Drug Other Name: Topical retinoid; \[brand name if applicable\] Description: Adapalene gel 0.1% is applied topically to the affected irradiated skin at a dose of 2 g per application, once daily, for 25 days.

BiafineActive comparator

Intervention Name: Biafine topical emulsion Intervention Type: Drug Other Name: Biafine (trolamine-based topical emulsion) Description: Biafine topical emulsion is a standard topical agent for the prevention and treatment of radiation-induced skin reactions. In this study, it serves as the active comparator. Participants in the control arm will apply Biafine emulsion topically to the irradiated skin field at a dose of 2 g per application, once daily, starting on the first day of radiotherapy and continuing throughout the entire course of radiotherapy (approximately 25 days, i.e., 25 fractions, or until completion of radiotherapy, whichever comes first). Participants will be instructed to gently apply a thin layer to clean, intact skin within the irradiated field and to avoid washing the treated area for at least 4-6 hours after application.

Drugs: Adapalene gel 0.1%, Biafine topical emulsion

Sites

1 site in 1 country

  • Yunnan Cancer HospitalKunming, Yunnan, China